Scilex Holding (SCLX) Depreciation & Amortization (CF) (2022 - 2026)

Scilex Holding (SCLX) posted quarterly Depreciation & Amortization (CF) of $2.9 million for Q1 2026, up 186.04% year-over-year from $1.0 million in Q1 2025, and up 80.78% on a QoQ basis from $1.6 million in Q4 2025.

Scilex Holding (SCLX) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends

Scilex Holding (SCLX) has reported Depreciation & Amortization (CF) for 5 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Depreciation & Amortization (CF) rose 186.04% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $6.5 million (up 61.5% YoY), while the FY2025 annual figure was $4.6 million, up 14.26% from the prior year.
  • Depreciation & Amortization (CF) came in at $2.9 million for Q1 2026 at Scilex Holding, up from $1.6 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $2.9 million in Q1 2026, with the low at $944000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $1.2 million, with a median of $1.0 million recorded in 2024.
  • Across the five-year window, Depreciation & Amortization (CF) slipped 3.27% in 2024 and soared 186.04% in 2026, its largest moves.
  • Year by year, Depreciation & Amortization (CF) stood at $1.0 million in 2022, then declined by 0.1% to $1.0 million in 2023, then fell by 2.9% to $1.0 million in 2024, then surged by 58.07% to $1.6 million in 2025, then surged by 80.78% to $2.9 million in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $2.9 million, $1.6 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 509.00 Mn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 2.00 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 188.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 1.37 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 581.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.12 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 93.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 1.61 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn 2.87 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.87 Mn
Mar 31, 2026 2.87 Mn
Dec 31, 2025 1.59 Mn
Dec 31, 2025 1.59 Mn
Sep 30, 2025 1.02 Mn
Sep 30, 2025 1.02 Mn
Jun 30, 2025 1.01 Mn
Jun 30, 2025 1.01 Mn
Mar 31, 2025 1.00 Mn
Mar 31, 2025 1.00 Mn
Dec 31, 2024 1.00 Mn
Dec 31, 2024 1.00 Mn
Sep 30, 2024 1.01 Mn
Sep 30, 2024 1.01 Mn
Jun 30, 2024 1.01 Mn
Jun 30, 2024 1.01 Mn
Mar 31, 2024 1.03 Mn
Mar 31, 2024 1.03 Mn
Dec 31, 2023 1.03 Mn
Dec 31, 2023 1.03 Mn